Patient demographic characteristics, baseline characteristics, and numbers of bleeding events for all patients (N = 102)
| Characteristic . | Value . |
|---|---|
| Sex, N (%) | |
| Female | 43 (42) |
| Male | 59 (58) |
| Age, median (range), y | 74 (26-97) |
| Underlying disorders, N (%) | |
| None/idiopathic | 68 (67) |
| Autoimmunity | 20 (20) |
| Malignancy | 13 (13) |
| Pregnancy | 5 (5) |
| Concomitant disorders, N (%) | |
| Coronary artery disease | 28 (27) |
| Heart failure | 30 (29) |
| Renal failure | 37 (36) |
| Arterial hypertension | 59 (58) |
| Type 2 diabetes | 28 (27) |
| WHO performance status, N (%) | |
| 0 | 15 (15) |
| 1 | 26 (25) |
| 2 | 23 (23) |
| 3 | 22 (22) |
| 4 | 15 (15) |
| 5 | 1 (1) |
| Baseline FVIII activity, median (range), IU/dL | 1.4 (<1-31) |
| Inhibitor, median (range), BU/mL | 19 (1-1449) |
| Bleeding events, no. of events/no. of patients | |
| All events | 289/93 |
| Events before or on day 1 | 148/80 |
| Events after day 1 | 141/61 |
| Characteristic . | Value . |
|---|---|
| Sex, N (%) | |
| Female | 43 (42) |
| Male | 59 (58) |
| Age, median (range), y | 74 (26-97) |
| Underlying disorders, N (%) | |
| None/idiopathic | 68 (67) |
| Autoimmunity | 20 (20) |
| Malignancy | 13 (13) |
| Pregnancy | 5 (5) |
| Concomitant disorders, N (%) | |
| Coronary artery disease | 28 (27) |
| Heart failure | 30 (29) |
| Renal failure | 37 (36) |
| Arterial hypertension | 59 (58) |
| Type 2 diabetes | 28 (27) |
| WHO performance status, N (%) | |
| 0 | 15 (15) |
| 1 | 26 (25) |
| 2 | 23 (23) |
| 3 | 22 (22) |
| 4 | 15 (15) |
| 5 | 1 (1) |
| Baseline FVIII activity, median (range), IU/dL | 1.4 (<1-31) |
| Inhibitor, median (range), BU/mL | 19 (1-1449) |
| Bleeding events, no. of events/no. of patients | |
| All events | 289/93 |
| Events before or on day 1 | 148/80 |
| Events after day 1 | 141/61 |
Part of this information has been included in a previous publication of the GTH-AH 01/2010 study.10